First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
He was appointed a Board member and the Chairman in 2012.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Biopharma and CROs to benefit from simplified access to global research sites
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
WuXi STA opens a new large scale continuous manufacturing plant
Better serving global partners and advancing healthcare innovation
Subscribe To Our Newsletter & Stay Updated
